Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Global Health
Novartis advances malaria therapy to Phase 3 study
by Michael McCoy
December 1, 2022
| A version of this story appeared in
Volume 100, Issue 43
Novartis and the nonprofit Medicines for Malaria Venture are planning Phase 3 clinical trials in 2023 of a nonartemisinin treatment for people with malaria. The drug candidate combines the new molecule ganaplacide with a new formulation of lumefantrine. The current gold standard in malaria treatment is an artemether-lumefantrine combination, but malaria-causing parasites are becoming resistant to artemisinin derivatives like artemether, Novartis says.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter